Healthcare

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

RA Capital has led a $100m series B round for Ventus Therapeutics, which is linked to multiple universities.

UC Berkeley's DNA-editing technology spinout has raised $10m from RA Capital in addition to the $65m it pocketed in November.

RA Capital Management has led a series B round for the UW-linked vaccine developer, which had raised $51m in a series A 18 months ago.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Fraunhofer Society has found minimal impact from lockdowns and the pandemic on the number of spinouts its institutes were able to generate last year.

Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.